Who are BPaL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MDR-TB Treatment Regimen(WHO), New regimen(BdqCfzLzd+XY).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bpal.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

BPaL — Competitive Intelligence Brief

BPaL (BPaL) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antituberculous combination therapy. Area: Infectious Disease.

phase 3 Antituberculous combination therapy Mycobacterial ATP synthase (bedaquiline), mycobacterial DNA/proteins (pretomanid), bacterial ribosome (linezolid) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

BPaL (BPaL) — Otsuka Pharmaceutical Development & Commercialization, Inc.. BPaL is a three-drug combination regimen (bedaquiline, pretomanid, and linezolid) that inhibits mycobacterial ATP synthase and protein synthesis to kill drug-resistant tuberculosis bacteria.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BPaL TARGET	BPaL	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Antituberculous combination therapy	Mycobacterial ATP synthase (bedaquiline), mycobacterial DNA/proteins (pretomanid), bacterial ribosome (linezolid)
MDR-TB Treatment Regimen(WHO)	MDR-TB Treatment Regimen(WHO)	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Antituberculous combination therapy
New regimen(BdqCfzLzd+XY)	New regimen(BdqCfzLzd+XY)	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Antituberculous combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antituberculous combination therapy class)

Shanghai Pulmonary Hospital, Shanghai, China · 2 drugs in this class
Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BPaL — Competitive Intelligence Brief. https://druglandscape.com/ci/bpal. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab